Evidence map›Paper›PMID 40623504›Full record

ReviewAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2025

Sensitization in Transplantation Assessment of Risk 2025 innate working group: The potential role of innate allorecognition in kidney allograft damage.

Olivier Thaunat, Fadi G Lakkis, Vasilis Kosmoliaptsis, Carrie Schinstock, Anat Tambur, Sebastiaan Heidt, Maarten Naesens

Abstract readReview
In one paragraph

Review in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Tailoring HLA antibody monitoring post-transplantation.Pediatric nephrology (Berlin, Germany) · 2026
    Article
  2. Article
  3. Review
  4. Review
  5. The Top 12 Most Impactful Papers in Clinical Transplantation in 2025: TI Editors' Choice.Transplant international : official journal of the European Society for Organ Transplantation · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Olivier ThaunatLyon-Est Medical Faculty, Claude Bernard University, Lyon, France; Department of Internal Medicine, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France; Centre International de Recherche en Infectiologie, INSERM U1111, Université Claude Bernard Lyon I, Centre National de la Recherche Scientifique UMR5308, Ecole Normale Supérieure de Lyon, Lyon, France.
Fadi G LakkisDepartments of Surgery, Immunology, and Medicine, Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Vasilis KosmoliaptsisDepartment of Surgery, University of Cambridge, Cambridge, UK.
Carrie SchinstockDivision of Hypertension and Nephrology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Anat TamburDepartment of Surgery, Comprehensive Transplant Center, Northwestern University, Chicago, Illinois, USA.
Sebastiaan HeidtDepartment of Internal Medicine, Nephrology and Transplantation, Erasmus Medical Centre Transplant Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.
Maarten NaesensNephrology and Renal Transplantation Research Group, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium. Electronic address: maarten.naesens@kuleuven.be.

Funding

Innate Recognition of Allogeneic Non-SelfR01AI099465 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LAKKIS, FADI G. · 2012 to 2022
$4.1M
Innate Allorecognition in Clinical Organ TransplantationR01AI172973 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Fadi G. Lakkis · 2023 to 2026
$2.8M
NIAID NIH HHS R01 AI099465NIAID NIH HHS R01 AI172973
6 · The paper itself

Abstract

In solid organ transplantation, the alloimmune response is traditionally attributed to the action of alloreactive T cells that recognize mismatched human leukocyte antigens, as well as antibody formation and antibody-mediated rejection. However, recent evidence indicates that these paradigms of involvement of the adaptive immune system in organ transplant rejection do not explain all cases of graft inflammation and that innate cell allorecognition plays a role. This review, conducted by the innate team of the Sensitization in Transplantation Assessment of Risk workgroup, summarizes the concepts and empirical evidence supporting innate allorecognition. The focus is on natural killer cell activation via missing self and monocyte activation through the signal regulatory protein α-CD47 pathway and SIRPα gene polymorphisms. A consensus definition of genetic missing self is proposed, necessitating both donor and recipient human leukocyte antigen class I genotyping and evaluation of the recipient inhibitory killer-cell immunoglobulin-like receptor genotype. Although in vitro studies and preclinical validations corroborate the potential of innate allorecognition concepts, further research is required to establish clinical utility. This article delineated future research directions to bridge the gap between theoretical promise and practical application in clinical transplantation.

Indexed as

Graft RejectionImmunity, InnateKidney TransplantationKiller Cells, NaturalAllograftsGraft SurvivalHumansRisk AssessmentCD47KIRmonocytesNK cellstransplantation

Identifiers

PMID40623504
PMCPMC12331380

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.